| Keywords: |
cancer chemotherapy; clinical trial; cisplatin; doxorubicin; fluorouracil; interferon; ascites; cancer combination chemotherapy; antineoplastic agents; cytarabine; methotrexate; carboplatin; interleukin 2; peritoneal neoplasms; etoposide; antineoplastic combined chemotherapy protocols; melphalan; chlormethine; thiotepa; monoclonal antibody; digestive system cancer; immunotherapy; kinetics; drug mechanism; mitoxantrone; ovary carcinoma; malignant mesothelioma; bleomycin; mitomycin c; drug toxicity; drug administration; colon carcinoma; stomach carcinoma; therapy; peritoneum mesothelioma; clinical trials; stomach; pharmacokinetics; ascites fluid; streptozocin; female genital system; endocrine system; intoxication; peritoneal cavity; large intestine; intraperitoneal drug administration; injections, intraperitoneal; human; support, non-u.s. gov't; picibanil
|
